SGNLVA-002: Single arm, open-label, phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer Meeting Abstract

Industry Collaboration International Collaboration

cited authors

  • Cortes, J.; Diab, S.; Basho, R. K.; Oliveira, M.; Pluard, T.; Alemany, C.; Brown-Glaberman, U.; Meisel, J.; Boni, V.; Sinha, R.; Garcia Estevez, L.; Ettl, J.; Kuemmel, S.; Manso Sanchez, L. M.; Moon, Y. W.; Villanueva Vazquez, R.; Wuerstlein, R.; Wang, Y.; Wang, Z.; Han, H.

authors

Publication Date

  • September 1, 2020

webpage

published in

category

start page

  • S393

end page

  • S393

volume

  • 31